Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-arm phase II study to determine efficacy and safety of HAIC combined with tislelizumab and lenvatinib for advanced hepatocellular carcinoma (aHCC) with Vp3-4 portal vein tumor thrombosis (PVTT)

Next Previous
Search
Trial Profile

A single-arm phase II study to determine efficacy and safety of HAIC combined with tislelizumab and lenvatinib for advanced hepatocellular carcinoma (aHCC) with Vp3-4 portal vein tumor thrombosis (PVTT)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenvatinib (Primary) ; Tislelizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Liver cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Jan 2024 Results ( As of August 15, 2023, n=46) assessing efficacy and safety of HAIC combined with lenvatinib and tislelizumab in uHCC pts presented at the 2024 Gastrointestinal Cancers Symposium
    • 09 Jul 2023 New trial record
    • 06 Jun 2023 Results (n=22; data cutoff date: 20 Jan 2023) of preliminary efficacy and safety analysis presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top